Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

The Journal of antimicrobial chemotherapy - 1 Apr 2009

Malet Isabelle, Delelis Olivier, Soulie Cathia, Wirden Marc, Tchertanov Luba, Mottaz Philippe, Peytavin Gilles, Katlama Christine, Mouscadet Jean-François, Calvez Vincent, Marcelin Anne-Genevieve

Abstract excerpt

OBJECTIVES: Raltegravir is the first approved inhibitor of HIV-1 integrase (IN). In most patients, raltegravir failure is associated with mutations in the IN gene, through two different genetic pathways: 155 (N155H) or 148 (Q148K/R/H). The objective of this study was to characterize the dynamics of HIV-1 quasispecies variant populations in patients who failed to respond to raltegravir treatment. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase

Share to Inhibitory Concentration 50

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 19221102
DOI: 10.1093/jac/dkp014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.PMID 19221102Read ↗

Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance <i>In Vivo</i>Semantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.Semantic proximity Read ↗

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutationSemantic proximity Read ↗

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.Semantic proximity Read ↗

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.Semantic proximity Read ↗

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.Semantic proximity Read ↗

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.